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operation improved survival, especially in patients with
ipsilateral mediastinal nodal metastasis (N2).4 After these
promising results, the Southwest Oncology Group
(SWOG) devised a phase II trial intended to clarify
whether the benefits of induction therapy could be
extended to patients with stage IIIB disease.5-7 Albain
and colleagues6 concluded that there was no survival dif-
ference between stage IIIA and stage IIIB and reported
an encouraging 24% 3-year survival for the latter group.
However, stage IIIB NSCLC entails either lesions that
show a tendency towards distant spread (positive pleural
effusion; N3 disease) or locally infiltrative tumors that
involve by direct extension the mediastinal organs (T4
“mediastinum”). From a surgical point of view these lat-
ter tumors, which might be described as “T4 centrally
located” lesions, are often technically unresectable.
When a primary operation is attempted, the resection is
rarely complete and the long-term survival is a discour-
In the late 1980s a number of studies showed that stageIIIA non–small cell lung cancer (NSCLC) could be
downstaged and reconverted to surgical treatment by
induction chemotherapy or chemoradiotherapy.1-3 It was
also demonstrated that induction therapy followed by an
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INDUCTION CHEMOTHERAPY FOR T4 CENTRALLY LOCATED NON–SMALL CELL LUNG CANCER 
aging 8%.8 More than one half of the patients experience
local recurrence, and approximately 40% of the patients
have distant metastasis.9,10 Complete resection remains,
nevertheless, the mainstay in the treatment of NSCLC;
and with the enhancement offered by induction therapy,
it has been demonstrated in other settings that more com-
plete resections can be achieved. Also, systemic treat-
ment may prevent or reduce the development of distant
metastasis. On the basis of the optimistic results of the
group of Memorial Sloan Kettering Cancer Center4 with
induction chemotherapy for N2 disease, we were attract-
ed by the possibility of reconverting the subgroup of T4
unresectable lesions to operation. We therefore used
induction chemotherapy in a prospective clinical trial
intended to achieve resectability in patients with centrally
located T4 NSCLC.
Materials and methods
Between January 1990 and April 1996, we enrolled 57
patients with histologically confirmed NSCLC in a prospec-
tive single-institution clinical trial intended to evaluate the
efficacy of induction chemotherapy followed by an operation.
Only patients with centrally located T4 tumors were included
independently from the N status. All other types of stage IIIB
(cytologically positive pleural effusion; contralateral medi-
astinal or supraclavicular lymph node metastasis) and those
patients with distant metastasis were excluded. Pretreatment
evaluation included clinical history, physical examination,
complete laboratory work-up, chest radiography, electrocar-
diography, pulmonary function tests, total body computed
tomography (CT), and bronchoscopy. Bone scans and mag-
netic resonance (MR) were selectively used. The eligibility
criteria for T4 were as follows:
1. Clinical: superior vena cava (SVC) syndrome (9
patients), vocal cord paralysis (6 patients), dysphagia from
esophageal involvement (1 patient).
2. Radiologic: CT and MR evidence of infiltration (10
patients). This group was subjected to a potential margin of
error. We were conscious of this risk and had made all efforts
to restrict the number of these patients. Because it is the rule
in our Department, all CT and MR images were reviewed by
us before a final decision was reached. In 2 patients the tumor
surrounded the SVC for more than 50% of its circumference
without causing SVC syndrome; 2 patients had erosion of the
vertebral body; 3 patients experienced the sudden appearance
of atrial fibrillation associated with a neoplasm occluding the
lower pulmonary vein and extending over the left atrium with
no cleavage plane; in 3 patients the tumor infiltrated the aorta
and the origin of the left pulmonary artery inside the peri-
cardium. Eight of these patients also had mediastinoscopy.
3. Bronchoscopic: Infiltration of the trachea, tracheo-
bronchial angle, or carina (11 patients).
4. Thoracoscopic: Histologically proven mediastinal infil-
tration (20 patients). Thoracoscopy was performed in these
patients as previously described.11,12
All patients fulfilling these criteria and undergoing induc-
tion chemotherapy at our institution between January 1990
and April 1996 were included in the study.
We did not use thoracotomy as a staging technique. Medi-
astinoscopy was performed in 38 patients. Four patients
underwent mediastinoscopy and thoracoscopy. All invasive
staging procedures (bronchoscopy, mediastinoscopy, and tho-
racoscopy) were performed by us. The standard chemo-
therapy protocol consisted of 3 cycles of the mitomycin-
vinblastine-platinum regimen. Cisplatin (120 mg/m2) was
administered intravenously in a 20-minute infusion with
hydration on days 1 and 29. Mitomycin (2 mg/m2) was
administered intravenously on days 1 to 5. Vinblastine (4
mg/m2) was administered on days 1, 8, 15, 22, and 29. One
to 3 weeks after completion of the induction chemotherapy,
the disease of each patient was completely reevaluated. The
disease was restaged by clinical examination, complete labo-
ratory work-up, chest radiography, total body CT, and bone
scan. The cardiorespiratory status of the patient was
reassessed by spirometry, blood gas analysis, and electrocar-
diography. Echocardiography, ventilation/perfusion lung
scans, Holter monitoring, and stress testing were selectively
performed in patients who were at risk. Patients in whom dis-
tant metastasis developed (5 patients), those who showed
local progression of disease (6 patients), and those having
severe toxicity related to the induction therapy (4 patients)
were not considered for an operation. All surgical procedures
were performed by the same team. Standard posterolateral
thoracotomy, pulmonary resection, and complete hilar and
mediastinal lymphadenectomy were attempted. The resection
of portions of the infiltrated mediastinal organs was per-
formed when necessary to obtain tumor-negative resection
margins. Multiple frozen section examinations were per-
formed routinely. The resection was recorded as complete
when all resection margins were negative. After the opera-
tion, patients with complete resection of the primary tumor,
with microscopically negative margins, and negative N1 and
N2 nodes did not receive additional treatment. Patients whose
disease appeared unresectable or who had microscopically
positive margins or positive N1 and/or N2 nodes received
additional chemotherapy (2 cycles of the same regimen),
radiotherapy (3.500 rad), or chemoradiotherapy. Postopera-
tive adjuvant therapy was started 3 to 6 weeks after the oper-
ation. Follow-up is complete for all patients. Survival is
reported by intent to treat and was calculated from the start of
induction chemotherapy with the product limit method by
Kaplan and Meier.13 Differences among curves were analyzed
by the log-rank test and the chi-squared test. Completeness of
resection, preinduction therapy N status, and histologic type
were evaluated as predictors of survival. All deaths were
included in the analysis.
Results
From January 1990 to April 1996, 57 patients were
entered in the study. There were 47 men and 10 women
with a median age of 59 years (range, 42-75 years).
Squamous cell carcinoma was the most common cell
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type and was found in 31 patients (54%). Eighteen
patients (31%) had adenocarcinoma, 6 patients (10%)
had large cell carcinoma, and 2 patients (3%) had
adenosquamous tumors. The invasive staging procedures
(thoracoscopy, mediastinoscopy) were performed by us
without complications. Of the 38 patients undergoing
mediastinoscopy, 26 patients had N2 disease. Seventeen
patients had only 2 of the scheduled 3 cycles, and in 13
patients the dose and timing of the administration of the
drugs had to be reduced or modified. The preinduction
and postoperation staging is reported in Table I. The list
of infiltrated organs is reported in Table II. Induction ther-
apy was generally well tolerated. The most common
toxic effects were similar to those reported in other stud-
ies that used the MVP regimen.13 Four patients experi-
enced major toxicities that precluded an operation. Only
those 4 patients had severe toxicity; there were no other
patients who had induction chemotherapy and were
removed before being included in the group of 57
patients. Nephrotoxicity caused by cisplatin occurred in 2
patients; severe neutropenia associated with recurrent
infection occurred in 1 patient, and severe mitomycin-
induced interstitial lung disease developed in 1 patient.
Eleven patients did not respond to induction therapy; 6 of
those patients had adenocarcinoma (54%); 4 patients had
squamous cell carcinoma, and 1 patient had large cell
carcinoma. Four patients had persistent biopsy-proven
airway disease; distant metastasis developed in 5 patients,
and 2 patients displayed local progression of disease.
Forty-two patients (73% of the entire study group; 36
men and 6 women; age range, 42-75 years; median, 58
years) responded to therapy and underwent thoracotomy.
Patients undergoing operation showed stability or regres-
sion of tumor on CT. Of the 20 patients who had histo-
logic evidence of N2 before induction and who under-
went an operation, 2 patients (10%) were converted to
N0, and 6 patients (30%) were downstaged to N1. No
patient N0 at preinduction staging was found to be N2
after the operation; however, 7 patients who were medi-
astinoscopy negative turned out to have N1 disease at the
time of the operation. Of 13 patients with central airway
invasion, 6 patients did not respond to induction therapy;
1 patient had chemotherapy-induced toxicity, and 6
patients underwent an operation. Of these, 1 patient had
incomplete resection, and 5 patients had complete resec-
tion. The surgical procedure was almost constantly com-
plicated by fibrosis and obliteration of tissue planes; the
tumor burden was often surrounded by a reactive growth
involving the previously infiltrated organs. The extensive
use of frozen sections proved crucial to avoid the unnec-
essary resection of mediastinal organs that seemed
macroscopically involved. Thirty-six patients (63% of the
initial study group and 85% of those undergoing opera-
tions) had complete resection. We performed 4 explorato-
ry thoracotomies, 6 pneumonectomies (1 incomplete
resection), and 32 lobectomies (1 incomplete resection).
Twenty procedures were associated with resection and
reconstruction of hilar and mediastinal organs. The
details of the surgical procedures are reported in Table III.
Six of 8 patients who were staged as T4 by CT and MR
had extended and complex operations (Table IV). In 3
patients the resection of the SVC was required. The vein
was reconstructed by a patch of autologous pericardium
in 2 patients and by an armored polytetrafluoroethylene
tube in 1 patient. Resection and reconstruction of the
bronchus and/or pulmonary artery was performed in 14
patients, with the technique previously described.14
Pathologic staging is reported in Table I. In 4 patients
(7% of the entire group and 9.5% of patients who had
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Table I. Staging before induction therapy (57 patients)
and at thoracotomy (42 patients)
Before 
induction therapy Thoracotomy
Stage IIIB (n=61)
T4 N2 34 4
T4 N1 6
T4 N0 17
Stage IIIA (n=13)
T3 N2 2
T3 N1 2
T3 N0 2
T2 N2 6
T1 N2 1
Stage II (n=13)
T2 N1 12
T0 N1 1
Stage I (n=8)
T2 N0 6
T1 N0 2
Stage 0 (n=4)
TOTAL 57 42
Table II. Mediastinal organs infiltrated by tumor in
57 patients
Organ No. of patients
Trachea 13
SVC 13
Esophagus 3
Atrium 3
Extensive mediastinal infiltration 13
Spine 3
Recurrent laryngeal nerve 6
Pulmonary artery 8
Aorta 5
Azygos vein 2
undergone thoracotomy), no histologic evidence of tumor
was found. Major complications occurred in 7 patients
(16%), 1 of whom died (2.3%). We had 2 bronchopleur-
al fistulas (1 death), 1 acute myocardial infarction, 2 cases
of severe respiratory insufficiency, 1 empyema, and 2
wound infections. Nine additional patients experienced
delayed lung reexpansion and prolonged air leaks. Chest
tube duration ranged between 4 and 17 days, excluding
the patients with bronchopleural fistula and empyema.
Postoperative adjuvant therapy was scheduled for
patients having incomplete resection and for those with
N1 or N2 disease. However, of 6 patients who had incom-
plete resection, 1 patient died of bronchopleural fistula
and 2 patients were too compromised to withstand further
therapy and died 6 months after the operation with local
recurrence. Follow-up is complete for all patients; 17 to
79 months (mean, 29 months) after the start of induction
therapy, 36 patients have died of cancer (18 patients, of
metastasis; 11 patients, of local recurrence; 4 patients, of
neoplastic cachexia; and 3 patients, of metastasis plus
local recurrence); 3 patients died of treatment-related
causes (chemotherapy related toxicity, bronchopleural
fistula, acute myocardial infarction 1 month after the
operation); 3 patients died of unrelated causes; 2 patients
are alive with disease; 13 patients are alive and free of
disease. With a 95% confidence limit, survival for all
patients is 61.4% (48.9%-73.9%) at 1 year and 19.8%
(8.3%-31.3%) at 4 years. Four-year survival was 25.9%
for the 42 patients who underwent an operation and
30.4% for the 36 patients having complete resection (Fig
1). Completeness of resection (P = .0075) and pretreat-
ment N status (P = .00009; Fig 2) significantly influenced
survival. Histology did not appear to influence survival (P
= .20).
Comment 
The prognosis of NSCLC with mediastinal invasion is
uniformly poor. Complete resection is feasible in only
22% to 60%, and the overall reported 5-year survival is
around 9%.15 Within this group, T3N0 lesions have a
more favorable outcome, but still the complete resection
rate does not exceed 66%.8 On the other hand, T3N1 or
N2 tumors and T4 lesions are resectable in no more than
20% of the cases, and their 5-year survival is a disap-
pointing 8%.8,9 Radiation therapy does not seem to be
more active with T4 lesions; a study from Shields and
coworkers16 showed that, although 26% of the tumors
were sterilized by radiation therapy, this had no effect
on survival. More recently, the use of hyperfractionated
very high-dose (>6000 cGy) radiotherapy could not
enhance survival to more than 29% at 2 years.17 All in
all, the prognosis of patients with T4 NSCLC involving
the mediastinum is dismal, and at the present time the
appropriate treatment has not been found. 
Because induction therapy based on the MVP regi-
men proved effective in downstaging N2 disease, we
have used it for unresectable T4 tumors. An induction
program of concurrent chemoradiotherapy could theo-
retically seem more appropriate for patients whose
major problem is a locally infiltrative, often large,
tumor burden associated with the threat of distant
metastases in 40% of cases. In this setting, however,
radiation therapy should be administered at high doses
and through extended mediastinal and pulmonary
fields. Our preceding experience with preoperative
radiotherapy for hilomediastinal NSCLC and its ensu-
ing postoperation complications helped us to avoid
radiation therapy; our perplexities were also confirmed
by Fowler and associates18 and by Rush and Benfield19
who underscored the risk of chemoradiotherapy in a
preoperative setting. On the other hand, the toxicity,
response rate, resectability, and survival in our study
are comparable to those reported in the SWOG trial6,7
in which chemoradiotherapy was used. We reduced the
cumulative doses of the drugs in 30 patients, but the
remaining 27 patients tolerated the full regimen well.
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Table III. Surgical procedures in 42 patients
Surgical procedure No. of patients
Exploratory thoracotomy 4
Pneumonectomy
Standard 3
Intrapericardial 2
Resection of atrium 1
Lobectomy/bilobectomy
Standard 15
Reconstruction of SVC 3
Pulmonary artery or bronchial sleeve 14
TOTAL 42
Table IV. Surgical procedures in 8 patients staged T4
by CT or MR imaging
Procedure No. of patients
SVC reconstruction 1
Extrapleural resection and shaving 1
of the vertebral body
Resection of the atrium 1
Intrapericardial pneumonectomy 1
Bronchial sleeve resection with implantation 1
of the bronchus intermedius at the carina
Sleeve resection of the pulmonary artery 1
Standard lobectomy 2
TOTAL 8
Our recommendation for the current clinical practice,
before the efficacy of new protocols is proved, is there-
fore to judiciously use the MVP regimen. Outside of
clinical trials, however, this regimen can be used with
more flexibility concerning the doses and timing of
administration.
Previous studies have grouped all stage IIIB tumors
on the basis of their known poor prognosis and because
this category of the disease of these patients is uni-
formly considered inoperable or unresectable. In this
case, “inoperable” suggests the concept of systemic
tumor involvement (eg, N3), and “unresectable” indi-
cates simply the technical impossibility to remove the
neoplasm. We elected to perform an operation in only
those patients with locally infiltrative T4 tumors
because this presentation of disease represents mainly
an operative problem. In fact, the tumor is often unre-
sectable, but (at least temporarily) it tends to expand
locally without systemic spread.8,10 This clinical be-
havior may recall the attitude of T3 tumors involving
the chest wall and thus further underscore the impor-
tance of complete resection. In selected patients with
T4 tumors that involve the carina, surgical resection is
indeed the treatment of choice.20 Also, occasional
patients have been treated successfully by the resection
of mediastinal organs, especially the SVC,21-23 aortic
arch,21 vertebral column,24 and main pulmonary
artery.25 Still, a few patients can benefit from these pro-
cedures, mainly because of the technical impossibility
to do so. Our goal was to explore the possibility of con-
verting unresectable T4 tumors into resectable tumors
and record the outcome of the tumors in these patients.
Accurate staging before induction therapy is crucial to
discriminate between T3 and T4.26 Clinical and bron-
choscopic confirmation of T4 is unquestionable and
uniformly accepted6,7 although CT and MR imaging,
mediastinoscopy, thoracoscopy, and thoracotomy each
have pros and cons that require special consideration.
Radiologic imaging is associated with a potential mar-
gin of error. We have studied mediastinal infiltration by
CT with intraoperative controls since 198127 and have
acquired a large direct experience in the field. Ten
patients in our group were staged radiologically: one
patient did not undergo an operation for tumor progres-
sion, and another patient did not undergo an operation
because of toxicity. For the 8 patients (19% of those
undergoing operation) who underwent an operation,
Table IV demonstrates that signs of previous or perma-
nent infiltration of the mediastinum were actually pre-
sent at the operation. Also, 8 of 10 patients underwent
The Journal of Thoracic and
Cardiovascular Surgery
Volume 117, Number 2
Rendina et al   229
Fig 1. Cumulative survival of T4 NSCLC undergoing induction chemotherapy: 57 patients, 1990 to 1996.
Survival is calculated for all 57 patients, for those undergoing surgery (42 patients), and for those having com-
plete surgical resection (36 patients).
mediastinoscopy, which proved positive in 4 patients.
The latter approach was accepted as a T4 staging
method in other studies6,7; however, mediastinoscopy
might be a source of incertitude as well, because it can
hardly discriminate between extracapsular N2 and pri-
mary tumor infiltration. Thoracoscopy might also suffer
to some extent from interoperator discrepancies because
of the limited view field, the impossibility to directly
palpate the tissues, and the risk of dissecting the lung
and mediastinum. Although we were satisfied with the
use of thoracoscopy in this setting,12 theoretically some
tumors could be downstaged to T3 by a more aggressive
(though dangerous) dissection. In this study, we have
made all efforts to be rigorous with the staging.
Therefore CT imaging was accepted only in selected
cases; otherwise thoracoscopy was performed. On the
basis of our experience, we would now suggest that, in
experienced hands, CT could be more often accepted for
the diagnosis of T4. As far as thoracotomy is concerned,
we do not consider it acceptable as a staging method.
Furthermore, if positive evidence of T4 must be
acquired by this technique, that should occur only after
thoracoscopy proved inconclusive, thus demonstrating
that the case is a particularly difficult one. The surgeon
is therefore expected to accept for his or her patient and
for him or herself a long-lasting, difficult, and danger-
ous operation.
Overall, the staging of T4 does not benefit at the
present time from precise guidelines; we have to rec-
ognize that there is no such specific technique avail-
able, such as mediastinoscopy, which exists for N2. If
clinical experimentation in this field has to be pursued,
precise staging guidelines should be developed that
take into account accuracy and patient safety. 
Toxicity, morbidity, and death related to the protocol
do not differ from what has been extensively reported
for chemotherapy-alone induction protocols.3,4 We
reduced the total dose of mitomycin in 23 patients. One
patient was removed from the study because of mito-
mycin-induced toxicity, and one patient, who is alive
and free from tumor 50 months after the operation, has
a stabilized form of interstitial lung disease. Our toxic-
ity-related mortality rate of 7% does not exceed that
reported in studies on chemoradiotherapy (10%).6,7
Also, the complete resection rate in our study is in line
with the reports of Faber and associates2 (85%),
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Fig 2. Cumulative survival of T4 NSCLC undergoing induction and surgery: 42 patients, 1990 to 1996. Survival
differences after lymph node status. Survival is calculated for patients with N2 disease (20 patients), for patients
with N1 disease (6 patients), and for patients with N0 disease (16 patients). 
Martini and colleagues4 (65%), and Rush and cowork-
ers7 (83%). We want to point out, however, that most
tumors in our series were technically unresectable
before induction therapy, and this furthermore empha-
sizes the efficacy of preoperative chemotherapy.
Surgical difficulties after induction chemotherapy
have been uniformly reported. In more than 50% of our
patients who underwent resection, the procedure was
complicated by the excision of hilar or mediastinal
organs; in the remaining cases, a standard lobectomy or
pneumonectomy could be carried out only after accu-
rate and difficult dissection. It seems that in our series
more reconstructive and “complex” procedures
occurred in comparison with other studies. First, we
tend to attribute this fact to our preference for bron-
chovascular reconstructive procedures as opposed to
pneumonectomy. Also, we had the impression that
lesser resections, such as sleeve lobectomy, could be
accomplished because of induction therapy. Second,
most studies on induction chemotherapy were based on
N2 lesions, which may be not so locally infiltrative as
T4. There is general agreement that the lung parenchy-
ma should be spared at all costs and that the clinical
course of these patients is often difficult. We believe
that surgical judgment and perioperative care rather
than technical ability is the key factor in this setting. Of
23 patients who died of cancer after an operation, 14
patients (60%) had distant metastases and only 7
patients (30%) had local recurrence. We interpret this
data as a confirmation of the efficacy of induction
chemotherapy in the local control of NSCLC. Survival
is promising for the entire surgical group but still dis-
appointing for patients either whose disease remained
inoperable or who had incomplete resection or N2 dis-
ease. However, in the N2 group some patients survived
more than 3 or 4 years; we infer that if more effective
chemotherapy regimens will become available, proba-
bly also this subset could benefit from resection.
Central airway involvement is an interesting feature
within the T4 stage, because it can be easily and reli-
ably monitored noninvasively. About one half of our
patients did not respond to the induction regimen, and
the other half had an operation. Two of the patients in
the latter group are free of disease after 18 and 34
months. This suggests that although the overall out-
come is not optimistic, downstaging of central airway
disease can be achieved and cure is possible.
We conclude that, in patients with T4 lesions who
underwent induction chemotherapy, it is reasonable to
attempt resection. The complete resectability rate in
our group was 63% (including patients who did not
undergo an operation), a rate significantly higher than
that reported in patients treated by primary surgery.8-10
Four patients had major toxicity from the induction
regimen (7%), and 3 patients died of treatment-related
causes (5.2%). Four-year survival is 19.5% for the
entire group and 25.9% for those undergoing an opera-
tion. Our data indicate that induction chemotherapy is
effective for downstaging and surgical reconversion of
centrally located, unresectable T4 NSCLC. Toxicity,
morbidity, and mortality rates are acceptable; survival
is promising, but it remains to be confirmed in larger
series of patients and phase III trials. 
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Discussion
Dr L. Penfield Faber (Chicago, Ill). I would like to com-
pliment Dr Rendina and his group on undertaking the treat-
ment of this group of patients with clinically advanced lung
cancer. These patients are extremely difficult to treat and
achieve good therapeutic results.
I would like to caution those in the audience who have just
heard this program of neoadjuvant chemotherapy, that it is a
rigorous treatment protocol. One hundred and twenty mil-
ligrams of cisplatin per meter square can be difficult for the
patient to tolerate the total dose, and mitomycin is associated
with an increased incidence of pulmonary fibrosis and pul-
monary complications after a surgical procedure. It is noted
in your series that 30 patients had their total dosages modified
and that a second group of patients received only 2 cycles
with a decrease in the amount of drugs given. With your
reported modifications, would you now recommend the same
drug protocol, or due to toxicity associated with this vigorous
program, would you now modify the recommended drug
dosages?
It is noted that this neoadjuvant program has sterilized 7%
of the tumors that were resected. Previous reports of neoad-
juvant programs that use chemotherapy in combination with
radiation report a sterilization rate of 18% to 20%, although
the tumors may not be as clinically advanced as those in your
series. Would this decreased incidence of tumor sterilization
in the resected specimens alter your thinking concerning the
use of radiation in combination with chemotherapy in the
treatment of this group of patients?
Staging was accomplished by thoracoscopy in 20 patients,
and I would question its use in clinical staging. It requires an
additional anesthetic and procedure and may well disturb
mediastinal tissue planes with possible seeding of tumor from
biopsy sites. It was stated in the article that your group has
had a great deal of experience with the CT scan and MR
imaging in staging, and with the addition of the PET scan and
mediastinoscopy, precise clinical staging could be accom-
plished without thoracoscopy. Would you recommend contin-
uation of thoracoscopic clinical staging?
Another question relates to the concept of downstaging T4
disease. In other words, if there is viable tumor in the main-
stem bronchus, can you convert a probable pneumonectomy
to a standard lobectomy or sleeve lobectomy by neoadjuvant
chemotherapy? Down staging also relates to mediastinal
lymph nodes. In your series, did you convert any positive N2
lymph nodes to N0, as determined by surgical/pathological
staging? This finding would further substantiate the efficacy
of your neoadjuvant chemotherapeutic protocol.
The described postoperative adjuvant therapeutic program
had variability, and specific indications were not provided in
the article. Some patients with positive margins and/or posi-
tive nodes received radiation; some received chemotherapy,
and some received both. Could you provide us with specific
recommendations for postoperative adjuvant therapy, and is
this type of therapy associated with any toxic manifestations?
The survival curve indicates that the patients with N0 dis-
ease had very good survival, while those with N1 and N2 dis-
ease did not do as well. With the poor results achieved in the
group of patients with T4 N2 disease, would you now recom-
mend routine mediastinoscopy in all patients submitted to
this protocol? What is your definitive recommendation in a
patient clinically staged with a T4 N2 disease? Should such a
patient be submitted to neoadjuvant therapy followed by
attempted surgical resection?
Dr Rendina. Indeed what you pointed out about the toxic-
ity of our induction therapy regimen is true. Over one half of
our patients had to undergo a modification of the chemother-
apy regimen despite the absence of radiotherapy in the proto-
col. Two of the 4 patients who could not undergo an opera-
tion because of the toxic side effects of chemotherapy had
nephrotoxicity. One other patient had multiple infections
associated with neutropenia, and in the fourth patient intersti-
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tial lung disease occurred. We closed our study in 1996 also
because the MVP regimen that we had been using was prob-
ably no more the best option for our patients. A protocol
including platinum and gemcitabine would probably be more
effective and less toxic, and we have it currently under inves-
tigation at our institution.
As far as sterilization of tumor is concerned, its rate is
indeed lower in our group of patients than that obtained by
other regimens. However, the sterilization rate per se does
not necessarily translate into an increased complete resec-
tion rate and better long-term survival for the whole study
group. What probably is more meaningful is the 63% over-
all complete resection rate that we report; these data paral-
lel the 85% complete resection rate in the group of patients
who underwent an operation. We believe this is the data to
look at, especially in the setting of direct mediastinal tumor
infiltration.
Staging is a very important issue in this setting, and we
think that CT and MR imaging are dependable in many cases.
Since 1981 we review in our department all CT images of our
patients with lung cancer, comparing the images accurately
with the intraoperative findings. With all due respect to the
radiologists, I think that this probably gives us a better idea of
the cleavage planes and tumor infiltration pattern, thus allow-
ing for better interpretation of successive cases. Twenty
patients underwent staging by video-assisted thoracoscopy. I
agree with you that this is a questionable choice, and we have
commented on our reasons for doing so in our article. All in
all, we have used VATS in those cases where we were not
100% sure of the CT imaging, and retrospectively we found
out that CT was very accurate in many patients. If clinical
studies have to be pursued in the field of infiltrative, centrally
located NSCLC, there is no doubt that one important point
would be to establish precise staging guidelines to be followed
by all investigators.
In our group, 38 patients underwent mediastinoscopy, and
in another 7 patients evidence of N2 disease was acquired by
VATS. Mediastinoscopy is an excellent tool for the staging of
N2 disease, but I would not say the same for T4. It is impos-
sible by mediastinoscopy to discriminate between extracap-
sular nodal infiltration and infiltration by direct extension of
the primary lung tumor. PET scanning seems promising in
this setting, but it is not yet available at our institution, and we
have no direct experience with this technique.
In our series, we observed a number of lesions that dis-
played endobronchial growth at the onset of disease. Patients
who were diagnosed endoscopically to have infiltration of
either the carina or the main stem bronchus and in whom the
tumor shrunk were treated according to the result of frozen
sections. Sleeve pneumonectomy or pneumonectomy were
avoided in favor of sleeve lobectomy whenever possible. We
have done that in several cases, and we have experienced no
local recurrence in the airway so far.
One of the slides showed that, indeed, 34 patients who had
N2 disease at the onset were downstaged to N1 or N0 at the
operation. This is probably a good result per se, but the sur-
vival of these patients is still disappointing.
The issue of postoperative therapy is, as you most correctly
pointed out, a controversial one. We started our study in 1990
with the idea of the administering adjuvant therapy to all
patients who either did not have a complete resection or who
had pathologic N1 and N2 disease. We have found, however,
that it is difficult to administer postoperative adjuvant thera-
py on a regular basis in these patients, because their general
conditions might be too compromised to safely allow it.
Although we do not have specific data, we have had the
impression that postoperative therapy does not appear to
influence survival.
Dr Walter Weder (Zurich, Switzerland). What is your
operative strategy after neoadjuvant chemotherapy if you
have a major response? When do you perform a minor resec-
tion, and based on what analysis do you decide?
Dr Rendina. Intraoperative frozen sections are of first
importance because the operative field is difficult to interpret
macroscopically after induction therapy. We have noticed that
instead of being a guide toward a more extended resection,
frozen sections have been a guide to restrict and limit the
resection. There were many patients in our series in whom
either the SVC or the adventitia of the aorta seemed infiltrat-
ed by tumor. We then realized by frozen sections that there
was no tumor infiltration but simple reactive tissue, which
could be left in place. This, of course, also applies to the
resection of the bronchus and pulmonary artery.
Dr Carlos Saldarriaga (Medellin, Colombia). Did you do
muscle transposition for the bronchial stump in all patients?
Dr Rendina. When we are planning to perform a sleeve
resection, which happens as Dr Faber pointed out earlier,
when one major bronchus was infiltrated before induction
therapy, we take down the intercostal muscle to wrap the
anastomosis at the end of the procedure.
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